Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01587469 · ClinicalTrials.gov registry record

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

A clinical trial, sponsored by Cepheid.

Completed
Registry status
992
Enrollment target

NCT01587469: Completed study, sponsored by Cepheid.

NCT01587469 is a clinical trial that has completed, run by Cepheid. The registered enrollment target is 992 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01587469 has completed, sponsored by Cepheid.

COMPLETED
Registry status
992 participants
Enrollment target

Study Summary

This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB. The sensitivity and specificity of the Xpert MTB/RIF (Mycobacterium tuberculosis/rifampin) assay performed on the first sputum collected for Xpert testing will be compared to gold standard conventional culture methods on two sputum specimens, in HIV-infected and HIV-uninfected participants.

Trial Details

FieldValue
Enrollment Target 992 participants
Start Date 2012-05
Est. Completion 2014-02-21
Cepheid

7 total trials

What the finished NCT01587469 record still lists

NCT01587469 is an observational study that tracks outcomes without assigning an intervention. The registered 992 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01587469 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01587469 about?

NCT01587469 is a clinical study titled "Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects". This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB. The sensitivity and specificity of the Xpert MTB/RIF (Mycobacterium tuberculosis/rifampin) assay performed on the f...

What is the current status of trial NCT01587469?

This trial is currently completed. The enrollment target is 992 participants. The study started on 2012-05. Estimated completion is 2014-02-21.

Who is sponsoring clinical trial NCT01587469?

This trial is sponsored by Cepheid, which has 7 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05987241 · 992 participants · Phase 2

    Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  • NCT05437575 · 994 participants · Phase 3

    Prehospital Analgesia INtervention Trial (PAIN)

  • NCT06671704 · 994 participants · NA

    GC-PRO Intervention

  • NCT05441709 · 990 participants · NA

    Furthering Equity Through Infant Feeding EDucation and Support

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01587469, the US trial registry maintained by the National Library of Medicine. NCT01587469 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.